ClinicalTrials.gg
Status unknownNCT03485599Updated Apr 2, 2018

Prevalence,Knowledge and Attitude of HIV /AIDS in Luxor

An observational study in HIV/AIDS, sponsored by Assiut University. Status unknown at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2018-04-02.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
400
Sex
All
01

Study summary

Human immunodeficiency virus infection is a global pandemic problem. About 35.3 million infected people in the world, so causing a great social, economical, political and cultural problems worldwide.

In 1986 Egypt's first AIDS case was discovered , since then the number of infected cases cases are increasing.According to United Nations 2016 statistics, there are about 11,000 infected people living with Human immunodeficiency virus in Egypt.

Read the detailed description

Human immunodeficiency virus is a lentivirus that causes the infection and over time leading to Acquired immunodeficiency syndrome.

The virus spread primarily by unprotected sex including vaginal, anal and oral sex, contaminated blood transfusions, infected needles, and from mother to child during pregnancy, delivery, or from milk during breastfeeding.

In 1986 Egypt's first AIDS case was discovered , since then the number of infected cases cases are increasing.According to United Nations 2016 statistics, there are about 11,000 infected people living with Human immunodeficiency virus in Egypt.

According to the National Aids Program, the primary mode of transmission is heterosexual intercourse, followed by homosexual intercourse , renal dialysis , and blood transfusion Others include street children, prisoners, and refugees, female sex workers, men have sex with men, and injecting drug users.

Human immunodeficiency virus related stigma and discrimination is a great barrier to effectively fighting the disease epidemic.

This study will assess prevalence, knowledge, attitudes of Human immunodeficiency virus and Acquired immunodeficiency syndrome people in Luxor Governorate in Upper Egypt.

02

Conditions studied

03

In context

Acquired Immunodeficiency Syndrome

3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.

This study's planned enrollment of 400 is above the median of 289 across 504 observational studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Community based cross sectional study will be done in Luxor,Data will be collected by physicians at the mobile Voluntary Confidential Counseling and Testing centers apart of National strategic plan , blood samples will be taken by laboratory technician,diagnostic tests will be done.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1-People living in Luxor. 2 Subjects of high risk groups as men have sex with men, children street, female sex workers.

3-People clinically diagnosed as /AIDS. 4-People in contact with HIV/AIDS patients.

Exclusion criteria

Exclusion Criteria:

1 - Subjects outside Luxor 2- People refused to consent 3- Mentally disordered patients

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • HIV infected people

    Blood samples will be taken and rapid HIV test by ELIZA will be done ,for positive cases Westron blot done

    Diagnostic Test: ELIZA , Westron blot

Interventions

  • Diagnostic testELIZA , Westron blot

    Blood sample will be taken then rapid test by ELIZA will be done if positive then confirmatory test by Westron blot will be done

06

What researchers measure

Primary outcomes

  1. knowledge score

    Questionnaire to define knowledge score of HIV/AIDS through an interview

    Time frame: 20 mintues

07

Study locations

1 site
  • Faculty of Medicine
    Assiut, 71111, Egypt
08

References and documents

Publications

  • Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest. 2008 Apr;118(4):1244-54. doi: 10.1172/JCI34706. PubMed 18382737 ↗
  • Abstracts from the 38th annual meeting of the society of general internal medicine. J Gen Intern Med. 2015 Apr;30 Suppl 2(Suppl 2):45-551. doi: 10.1007/s11606-015-3271-0. No abstract available. PubMed 25869016 ↗
  • Getnet MK, Damen HM. Level of stigma among female sex workers: comparison of two surveys of HIV behavioral data, Ethiopia. Afr Health Sci. 2011 Dec;11(4):543-9. PubMed 22649433 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2019; primary completion for Dec 2019, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2018
First posted
Apr 2, 2018
StartEst.
Jan 2019
Primary completionEst.
Dec 2019
CompletionEst.
Apr 2020
Last update
Apr 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03485599
Lead sponsor
Assiut University
Responsible party
Zienab Gamea (Principal Investigator, Assiut University) — Principal investigator
First posted
Apr 2, 2018
Start date
Jan 2019 (estimated)
Primary completion
Dec 2019 (estimated)
Completion
Apr 2020 (estimated)
Last update
Apr 2, 2018

Study contacts

Hisham Zayan, Assistant
Contact
hishamzayan@icloud.com
01223971409
Yasmine Mostafa, Lecturer
Contact
dr.yasminemostawfik@yahoo.com
01006033331
Hisham Zayan, Assistant
study director · Assiut University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion